No exceptions will be granted. 6.1 Inclusion Criteria 1) Signed Written Informed Consent Revised Protocol No.: 04 Date: 31-May-2019 69 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS a) The participant must sign the ICF prior to the performan ce of any study-related procedures that are not considered part of standard of care. b) The participant must sign the consent for pretreatment and on-treatment tumor biopsy samples at acceptable clinical risk, as judged by the investigator. i) Participants will be eligible to receive tr eatment upon completion of pre-treatment biopsy collection and confirmation that the biopsy sample has been sent for central analysis. ii) The solid tumor tissue specimen must be a c ore needle, excisional, or incisional biopsy. Biopsies of bone lesions that do not have a soft tissue component or decalcified bone tumor samples are also not acceptable. iii) Biopsied lesions s hould be distinct from index lesion(s) being evalu ated for radiological response. iv) An FFPE (block) sample must be sent for central analysis. v) If a participant had a biopsy in the preceding 90 days with no intervening anti-cancer therapy, participants can be enrolled without needing a repeat biopsy after discussion with the BMS Medical Monitor/Study Director (or designee) and upon confirmation of the availability of FFPE blocks. Participants will be required to undergo on-treatment biopsies at acceptable clinical risk as judged by the investigator in all arms. 2) Type of Participant and Target Disease Characteristics a) Participants must be at least 18 years old and have histological or cytological confirmation of metastatic and/or unresectable mali gnancy, including but not limited to CC, CRC, HNSCC, MEL, NSCLC, PRC, RCC, TNBC, and UCC with measureable disease per RECIST v1.1 (see Appendix 5 ) or PCWG3 (prostate only) (see Appendix 11) and have at least 1 lesion accessible for biopsy in addition to the target lesion. b) Presence of at least 1 lesion with measurable disease as defined by RECIST v1.1 or PCWG3 (prostate only) for solid tumors for response assessment. Participants with lesions in a previously irradiated f ield as the sole site of measurable disease will be permi tted to enroll provided the lesion(s) have demons trated clear progression and can be measured c) Participants must have received, and then progressed or been intolerant to, at least 1 standard treatment regimen in the advanced or metastatic setting, if such a therapy exists, and have been considered for all other potentially efficacious therapies prior to enrollment. Participants who are ineligible for standard therapy (due to medical factors such as co- morbid illness, age, etc.) will be allowed to enroll provided the reason for their ineligibility is documented in their medical records. d) Participants with prior exposure to therapy with any agent specifically targeting checkpoint pathway inhibition (such as anti-PD-1, anti-PD-L1, or anti-CTLA-4) are permitted after a washout period of any time greater than 4 weeks from the last treatment. e) For all parts (A, B1, B2, C1, C2, D, and E): i) Participants with CC, CRC, HNSCC, MEL, NSCLC, PRC, RCC, TNBC, and UCC will be permitted. Participants with other solid tumor histologies may be considered and Revised Protocol No.: 04 Date: 31-May-2019 70 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS eligibility s hould be discussed with BMS Medical Monitor/Study Director (or designee). f) For all parts (A, B1, B2, C1, C2, D, and E) i) The participant must consent for pretr eatment and sequential treatment (2 weeks after first dose of study treatment and 12 weeks after first dose) tumor biopsy samples. ii) The pretreatment and sequential biopsy samples should be from the same lesion, if possible. Thus, lesion that is > 3 cm at baseline s hould be considered for co llecting biopsy samples. A different lesion may be used to collect on-treatment biopsies should the original lesion not be available.